Meeting
2020 Gastrointestinal Cancers Symposium
Tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma.
Authors
Harry H. Yoon
Mayo Clinic, Rochester, MN
Harry H. Yoon , Ken Kato , Richard Hubner , Eric Raymond , Aiyang Tao , Sumei Liu , Ibrahim Qazi , Jian-Ming Xu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Esophageal and Gastric Cancer and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03783442
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr TPS462)
Abstract #
TPS462
Poster Bd #
L6
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A randomized, placebo-controlled, phase III trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC).
First Author: Jian-Ming Xu
Poster
2020 Gastrointestinal Cancers Symposium
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first‑line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
First Author: Rui-hua Xu
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Tislelizumab plus chemotherapy (chemo) versus placebo plus chemo as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: RATIONALE-305 European/North American patient subgroup.
First Author: Hendrik-Tobias Arkenau
Poster
2021 Gastrointestinal Cancers Symposium
Pembrolizumab plus chemotherapy for previously untreated, HER2-negative unresectable or metastatic advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859.
First Author: Josep Tabernero